Nils B. Jorgensen

Soborg, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

A Prediction Model for Cardiovascular Death in Individuals with Prediabetes.

A Prediction Model for Cardiovascular Death in Individuals with Prediabetes.

Journal: Studies in health technology and informatics

Published: May 23, 2026

Predicting cardiovascular death in overweight/obese people with prediabetes using machine learning-a proof-of-concept study.

Predicting cardiovascular death in overweight/obese people with prediabetes using machine learning-a proof-of-concept study.

Journal: Cardiovascular diabetology

Published: January 05, 2026

Acarbose or Canagliflozin vs. Placebo to Ameliorate Post-Bariatric Hypoglycaemia: The Clinical Outcomes of the HypoBar I Randomised Clinical Trial.

Acarbose or Canagliflozin vs. Placebo to Ameliorate Post-Bariatric Hypoglycaemia: The Clinical Outcomes of the HypoBar I Randomised Clinical Trial.

Journal: Diabetes, obesity & metabolism

Published: September 12, 2025

Empagliflozin improves beta cell function independently of relief of glucotoxicity in patients with type 2 diabetes: results from a randomised cross-over study with insulin as comparator.

Empagliflozin improves beta cell function independently of relief of glucotoxicity in patients with type 2 diabetes: results from a randomised cross-over study with insulin as comparator.

Journal: Diabetologia

Published: May 22, 2025

Fat absorption and metabolism after Roux-en-Y gastric bypass surgery.

Fat absorption and metabolism after Roux-en-Y gastric bypass surgery.

Journal: Metabolism: clinical and experimental

Published: January 07, 2025

β-Cell Function and Sensitivity to Incretins Before and After Roux-en-Y Gastric Bypass in Individuals With Type 2 Diabetes.

β-Cell Function and Sensitivity to Incretins Before and After Roux-en-Y Gastric Bypass in Individuals With Type 2 Diabetes.

Journal: Diabetes

Published: November 20, 2024

High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.

High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.

Journal: Diabetes care

Published: November 05, 2024

Time-Restricted Eating is a Feasible Dietary Strategy in the Treatment of Complicated Type 2 Diabetes: The RESET2 Pilot Study.

Time-Restricted Eating is a Feasible Dietary Strategy in the Treatment of Complicated Type 2 Diabetes: The RESET2 Pilot Study.

Journal: Journal of nutrition education and behavior

Published: April 16, 2024

Canagliflozin or acarbose versus placebo to ameliorate post-bariatric hypoglycaemia - The HypoBar I randomized clinical trial protocol.

Canagliflozin or acarbose versus placebo to ameliorate post-bariatric hypoglycaemia - The HypoBar I randomized clinical trial protocol.

Journal: Diabetic medicine : a journal of the British Diabetic Association

Published: December 19, 2023

The effects of postprandial exercise and meal glycemic index on plasma glucose and glucoregulatory hormone responses after Roux-en-Y gastric bypass.

The effects of postprandial exercise and meal glycemic index on plasma glucose and glucoregulatory hormone responses after Roux-en-Y gastric bypass.

Journal: American journal of physiology. Endocrinology and metabolism

Published: September 27, 2023

The role of empagliflozin-induced metabolic changes for cardiac function in patients with type 2 diabetes. A randomized cross-over magnetic resonance imaging study with insulin as comparator.

The role of empagliflozin-induced metabolic changes for cardiac function in patients with type 2 diabetes. A randomized cross-over magnetic resonance imaging study with insulin as comparator.

Journal: Cardiovascular diabetology

Published: May 31, 2023

Primary weight loss failure after Roux-en-Y gastric bypass is characterized by impaired gut-hormone mediated regulation of food intake.

Primary weight loss failure after Roux-en-Y gastric bypass is characterized by impaired gut-hormone mediated regulation of food intake.

Journal: International journal of obesity (2005)

Published: February 02, 2023

Showing 1-12 of 51

Last Updated: 09/26/2026